The impact of differentiated service delivery (DSD) on retention in care and viral suppression in South Africa: A target trial emulation of routine care data

Amy N. Huber^{1¶*,} Lise Jamieson^{1,2¶}, Matthew P. Fox^{1,3}, Musa Manganye⁴, Lufuno Malala⁴, Thato Chidarikire⁵, Nthabiseng Khoza⁴, Brooke E. Nichols^{3,6}, Sydney Rosen^{1,3}, Sophie Pascoe¹

¹ Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

² The South African Department of Science and Innovation/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, Republic of South Africa

³Department of Global Health, Boston University School of Public Health, Boston, MA, USA ⁴ National Department of Health, Pretoria, South Africa,

⁵ World Health Organization

⁶Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

*Corresponding author: Amy N. Huber: ahuber@heroza.org

*These authors contributed equally to this work.

E-mail addresses of authors: ANH: ahuber@heroza.org LJ: Ijamieson@heroza.org MM: musa.manganye@health.gov.za LM: lufuno.malala@health.gov.za TC: chidarikiret@who.int NK: petrus.khoza@health.gov.za BN: brooken@bu.edu MF: mfox@bu.edu SR : sbrosen@bu.edu SP: spascoe@heroza.org

Keywords: South Africa, HIV, antiretroviral therapy, differentiated service delivery, outcomes

Word count: Abstract: 429 Main text: 4567

$\frac{1}{2}$	Abstract
2 3 4	Introduction
5	Replacing conventional, facility-based HIV treatment with less intensive differentiated service delivery
6	(DSD) models could benefit DSD clients and the health system, but its value depends on maintaining or
7	improving clinical outcomes. We compared retention and viral suppression between antiretroviral
8	therapy (ART) clients enrolled in DSD models to those eligible for but not enrolled in DSD models in
9	South Africa.
10	
11	Methods
12	We applied a target trial emulation (TTE) methodology to data from South Africa's electronic medical
14	record system (TIER.Net) for 18 clinics across 3 provinces and estimated retention in care (attended
15	clinic visit within 12 months) and viral suppression (<400 copies/ml ³) at 12, 24, and 36 months after
16	follow-up start date, defined as DSD enrollment date for the intervention arm and the first trial
17	enrollment period clinic visit for the comparison arm. Clients were eligible for DSD models if they were
18	≥18 years old, on ART ≥12 months, and had two suppressed viral load (VL) measurements, per prevailing
19	national guidelines. For the TTE, we designated eight 6-month target trial enrolment periods between 1
20	July 2017 and 1 July 2021. For each period, we estimated the risk differences for retention in care and
21	viral suppression by comparing those enrolled in DSD models to those not enrolled, using a Poisson
22	distribution with an identity link function. We report adjusted and unadjusted risk differences for clients
23	enrolled in DSD models and for DSD-eligible clients not enrolled in a DSD model.
24 25 26	Results and discussion
27	49,595 unique individuals were eligible for DSD enrolment over eight target trials, contributing to a total
28	of 148,943 trial-clients, of whom 17% (25,775) were enrolled in DSD models. The pooled adjusted risk
29	difference for retention in care between clients enrolled in DSD and those not enrolled in DSD was 3.2%

30	(95% confidence interval (CI) 1.6%; 4.7%) at 12 months, 4.2% (2.4%; 6.0%) at 24 months, and 4.4%
31	(2.0%; 6.8%) at 36 months. For viral suppression, the adjusted risk difference comparing DSD to non-DSD
32	was estimated to be 1.4% (-0.5%; 3.2%) at 12 months, 1.7% (-0.5%; 4.0%) at 24 months, and 1.4% (-
33	0.6%; 4.4%) at 36 months. Results remained consistent across target trials. Clients who were younger,
34	lived in urban settings, or had less ART experience at trial enrolment had lower retention.
35 36 37 38	Conclusions Clients enrolled in DSD models in South Africa had slightly better retention in care and similar viral
39	suppression to those who were eligible for but not enrolled in DSD. With better or equivalent outcomes,
40	DSD models can be assessed on the basis of non-clinic costs and benefits, such as changes in quality of
41	care and resource utilization.
42 43	Registration: Clinicaltrials.gov NCT04149782.

45 Introduction

46

47 In South Africa, as in other countries in sub-Saharan Africa (SSA), the use of differentiated service 48 delivery (DSD) models for HIV treatment is expanding rapidly [1,2]. For eligible antiretroviral therapy 49 (ART) clients, DSD models adapt the characteristics of service delivery, such as location and frequency of 50 healthcare system interactions, to meet the needs of different client groups. This approach is expected 51 to sustain clients' positive clinical outcomes, increase satisfaction with their care, and increase the 52 efficiency of healthcare systems by decongesting clinics, reducing pressure on healthcare providers, and 53 simplifying procedures[3,4]. Most DSD models are limited to "established" or stable ART clients who 54 have been on treatment for at least 6 months, have documented viral load suppression, and do not have 55 uncontrolled co-morbid conditions or HIV-related symptoms[5]. The proportion of established clients 56 enrolled in any DSD model, rather than remaining in conventional (non-differentiated) care, varies 57 widely by country and facility, based on guidelines, resources, and provider and client preferences, 58 among other factors[6].

59

60 South Africa, home to the world's largest HIV treatment program[7], offers three main less intensive 61 models for ART clients who are established on treatment and have documented viral suppression: 62 facility-based medication pickup points, external (out-of-facility) medication pickup points, and 63 adherence clubs. (In South Africa, these models are referred to as Differentiated Models of Care, or 64 DMOC and fall within the category of Repeat Prescription Collection strategies or RPCs.) The three 65 models for established ART clients are supported by the Central Chronic Medicine Dispensing and 66 Distribution (CCMDD) programme, the Central Dispensing Unit (CDU), or facility-based pharmacies. They 67 provide centralized medication packaging and delivery to clients, with options for pickup at either 68 facility pickup points within healthcare facilities or at external pickup points adjacent to facilities or

69	within communities[7–10]. Other DSD models, such as medication lockers and home delivery, have also
70	been implemented in South Africa, but on a much smaller scale.
71	
72	Several randomized trials and observational studies have reported the outcomes of clients enrolled in
73	South Africa's less intensive models [11–13] and in others outside South Africa[14] and found high rates
74	of retention in care and viral suppression after one or more years of model exposure, an unsurprising
75	result given that retention and suppression are also both eligibility criteria for model enrollment. Few
76	studies[15–17], however, have compared the outcomes of clients actively enrolled in DSD models to
77	those who are eligible for DSD models but remain in conventional care. It is these eligible-but-not-
78	enrolled clients who comprise the relevant comparison group.
79	
80	The absence of evidence about how clients' outcomes in DSD models compare to those of similar clients
81	remaining in conventional care hampers decisions about whether to expand differentiated service
82	delivery programs and how to update eligibility criteria. To help fill that gap, we assessed the
83	effectiveness of DSD by comparing clients on DSD to those eligible for but not on DSD on outcomes of
84	retention in care and viral suppression at 12, 24, and 36 months using routinely collected electronic
85	medical record data.
86 87 88	Methods
89	Using a target trial emulation approach, we analyzed routinely collected medical records from a sample
90	of public sector facilities. We compared the 12-, 24- and 36-month retention in care and viral
91	suppression outcomes of DSD clients to those eligible but not enrolled in DSD in South Africa at primary
92	health clinics between 1 July 2017 and 1 July 2021.
93	

94 Models of care

95

96	As noted above, DSD-eligible ART clients were either enrolled in one of three less intensive
97	differentiated models of care in use during our analysis – primarily facility-based medication pickup and
98	external medication pickup, along with adherence clubs for a smaller number of clients – or in
99	conventional (non-differentiated) care. Enrollment decisions were presumably based on client eligibility,
100	provider preference, the availability of each model at any specific healthcare facility, and the facility's
101	access to enrolment procedures (e.g. the CCMDD database). Features of the four models represented in
102	our analysis are described in Table 1. We were not able to distinguish between these in the TIER.Net
103	data and therefore could only evaluate the impact of all DSD models compared to conventional care,
104	rather than comparing DSD models with one another. The 2016 South African Adherence Guidelines
105	were used to define DSD eligibility and viral suppression in this analysis, as the majority of the
106	enrollment period fell within their period of coverage [18]. During the study period, eligibility for DSD
107	enrollment required clients to be non-pregnant adults with a minimum of 12 months of experience on
108	ART and at least two documented suppressed viral loads (<400 copies/ml). We note that under current
109	guidelines, the VL threshold for suppression is 50 c/mL and 3 month-dispensing is recommended.

110

111 Table 1. Description of widely used models of HIV treatment delivery in South Africa

Model	Description	
All models	During the study period, clients were expected to make at least two full	
	clinical visits per year (every 6 months). Prescriptions could be written for a	
	maximum of 6 months. Antiretroviral medications were dispensed in	
	quantities of 1, 2, or 3 months at a time.	
Conventional care	Clients attend the health care facility for all visits. At every visit, the client	
	checks in and registers, collects their client folder, has their vital signs taken	
	and sees a clinician, usually a nurse (full clinic visit). Established clients are	
	dispensed 2 or 3 months of medication at a time after the consultation with	
	the clinician. Conventional care requires 4-6 full clinic visits per year.	

Facility pickup points	Clients attend the primary healthcare facility for all visits. If a client meets enrollment criteria, they are offered the choice to enroll into the facility pickup model and receive a six-month prescription for their chronic medication. The client is dispensed 2 or 3 months of medication from the clinician on the day of enrollment and then collects their medication from the facility pickup point for the duration of the six-month prescription. For facility pickup point collections, the client proceeds directly to the medication collection point upon arrival at the primary healthcare facility	
	and is given a pre-packed medication distributed by the pharmacy assistant or other trained clinic staff member. Medication is pre-packed by either	
	CCMDD, a CDU, or the facility. This model requires 2 full clinic visits and 2-4 medication pickup visits to the facility per year.	
External pickup points	The external pickup point model operates on the same schedule as the facility pickup point model described above. The model differs in the form and location of the pickup point – instead of collecting at the facility, the client collects a pre-packed treatment supply from an external service provider. Medication is pre-packed by either CCMDD or a CDU. Types of external pickup points include private pharmacies (major national chains and independent pharmacies), community-based venues, and electronic medication lockers. This model requires 2 full clinic visits and 2-4 medication pickup visits to an external pickup point per year.	
Adherence clubs	The adherence club model operates on the same schedule as the facility and external pickup point models described above. Adherence clubs offer group-based medication delivery, with up to 30 clients receiving pre-packed treatment supply on the same day from a healthcare provider or trained staff member at a location either on-site at the healthcare facility or off-site at another suitable location within the community. Medication is pre- packed by either CCMDD, a CDU, or the facility. This model requires 2 full clinic visits and 2-4 medication pickup visits from an adherence club per year.	

113

114 Study sites and population

115

116 Data were drawn from 24 public-sector health facilities in four districts in three provinces of South Africa

117 (6 clinics in each district- West Rand and Ekurhuleni in Gauteng Province, King Cetshwayo in KwaZulu-

118 Natal Province, and Ehlanzeni in Mpumalanga Province). We purposively chose a mix of high- and

119 medium-volume facilities in urban and rural settings. All sites included offered at least one DSD model at

120 the time of data collection had at least 1,000 clients on ART and utilized South Africa's electronic

121 medical record system, TIER.Net[19]. The data extracted from the study sites spanned the period from

122 July 2017 to June 2023, depending on the district, and in 2021 the approximate proportion of ART clients

enrolled in DSD models ranged between 24% and 81%, with KwaZulu-Natal reporting the highestproportion of clients enrolled. (Supplementary Table S1).

125

126	The TIER.Net system[20] is a facility-based electronic register. Each client's health information is
127	recorded in a paper file at the point of care and then entered into TIER.Net by an on-site data capturer.
128	Data are collected prospectively, and inactive records are not deleted. The system allows for capture of
129	age, gender, HIV test date, ART start date, visit date, ART medication prescribed, and months of ART
130	dispensed for all clinic interactions, date and result of HIV-related laboratory tests, and the outcome
131	date and status for clients who have died, transferred, or become disengaged from care. A DSD model
132	enrollment variable was introduced in 2016, but with three limitations for DSD program monitoring.
133	First, out-of-facility medication collection from external pickup points and community-based adherence
134	clubs is not captured in TIER.Net—only actual clinic visits are recorded. Second, before June 2020, the
135	DSD enrollment variable did not distinguish among separate DSD models, but only the client's
136	enrollment in any non-conventional model. And third, unofficial (silent) transfers of clients between
137	facilities are not captured in TIER.Net, creating a potentially large discrepancy between facility-level and
138	overall ART program loss to follow-up [21]. To address these limitations, we grouped all DSD models
139	together, included a 12-month window for follow-up visit measurement, and reported facility-level
140	retention.

141

142 Target trial emulation

143

Target trial emulation is a methodology that simulates a hypothetical randomized clinical trial and can be applied to observational data in a way that assists in estimating causal effects[22]. It also helps to prevent immortal time bias, whereby a person can accrue person time in the study when they cannot

147	logically experience the outcome. Immortal time bias often occurs when the beginning of follow-up time
148	and intervention exposure are not aligned [23]. Using this methodology, we clearly described the
149	hypothetical trial we would like to have conducted and then attempted to mimic that trial as closely as
150	possible using observational data, potentially reducing bias in our assessment of the effect of DSD on
151	treatment outcomes.
152	
153	Table 2 outlines our hypothetical target trial and the choices we made in our observational study to best
154	emulate that trial. Both the target trial and the emulation sought to estimate the impact of enrollment
155	in differentiated service delivery (DSD) models on retention in care and viral load suppression at 12-, 24-
156	and 36- months after DSD eligibility. To do this, we used in both the trial and the emulation the DSD
157	eligibility criteria in the South African guidelines [21] in effect at the time of the study [18]. In addition,
158	we included in the emulation additional trial eligibility criteria in line with the conduct of our
159	hypothetical trial: 1) documentation of a recent clinic visit, within 6 months before the trial, and 2) no
1.60	

- 160 prior DSD enrollment recorded (DSD naïve at study enrollment).
- 161

162Table 2. Target trial emulation specification of differentiated service delivery (DSD) models care163

Component	Target trial	Emulated trial
Aim	To estimate the impact of differentiated service	Same.
	delivery (DSD) models on retention in care and viral	
	load suppression at 12-, 24- and 36-months post-	
	DSD eligibility in South Africa.	
Trial eligibility	Adults (aged 18 years or older) in South Africa living	Same.
	with HIV and are eligible for DSD by being on	
	antiretroviral treatment (ART) for at least 12	
	months, having at least two suppressed viral loads	
	(<400 copies/ml), being non-pregnant and being	
	DSD naïve (no prior DSD enrollment in record).	
Intervention	Enrolling in a DSD model at randomization with	Enrolling in a DSD model at baseline with
arm strategy	model of care after randomization determined by	model of care after enrollment
	the client and provider	determined by the client and provider
Comparison	Remaining in conventional care at randomization	Remaining in conventional care at
arm strategy	with model of care after randomization determined	baseline with model of care after
	by the client and provider	baseline determined by the client and
		provider
Intervention	Clients randomly assigned to DSD vs non-DSD	Clients non-randomly assigned to DSD
assignment	(comparison arm).	model. Randomization is emulated by

Component	Target trial	Emulated trial
		adjusting for baseline covariates: age,
		sex, urban/rural status, province
Data	TIER.Net is used for the passive collection of follow- up trial data. Passive data collection through routine medical care systems to avoid influencing the primary outcome of retention.	Same
Follow-up start date	Follow-up starts at intervention assignment	DSD: follow-up starts at the first DSD visit in the trial baseline. Non-DSD: follow-up starts at the first visit in the trial baseline.
Follow-up end date	Follow-up ends at death, loss to follow-up or at 36 months follow-up, whichever occurs first.	Same but with administrative censoring for each 12-, 24- and 36-month outcomes to ensure clients had sufficient potential follow-up data available to assess outcomes. Censoring was based on the date the data was extracted for each district, and clients were censored if the outer window for measuring each outcome went beyond the data extract date.
Outcome	 1) Retention in care at 12, 24 and 36 months, defined as having a clinic visit between 12-24, 24-36 and 36-48 months after intervention assignment, respectively. 2) Viral suppression at 12, 24 and 36 months, defined as having a viral load measured at <400 copies/ml between 12-24, 24-36 and 36-48 months after intervention assignment, respectively. 	Same.
Causal contrast	Intention-to-treat effect, i.e. effect of being assigned to DSD vs. non-DSD models at baseline, regardless of whether clients enrolled into a DSD model after baseline or those assigned to DSD remained on DSD after randomization.	Observational equivalent of intention-to- treat effect, i.e., the effect of being assigned to DSD vs non-DSD models at baseline, regardless of whether clients enrolled into a DSD model after baseline.
Statistical analysis	Risk difference model estimating retention and viral suppression in DSD vs non-DSD.	Same. Adjustment for baseline covariates did not substantially change the estimates.

164

165 Our target trial intervention was enrollment in a DSD model. After target trial randomization,

166 participants could return to standard care at the discretion of the client and the provider. We mimicked

167 this in our emulation by defining the intervention to be enrollment in DSD at baseline. After DSD

168 enrollment, participants could return to regular standard care, but we would still analyze them as if they

- 169 were in the DSD arm as per intention-to-treat, as would have been done in the target trial. The
- 170 comparison arm for our target trial was the participants randomized to not immediately enroll in a DSD
- 171 model. As would happen in routine care, however, comparison arm participants would be allowed to
- 172 enroll in a DSD model at a later time point after the enrollment period, should they be offered the

173	opportunity and accept it. This effectively alters our study question to comparing the effect of enrolling
174	in DSD immediately to the effect of a delayed opportunity for DSD enrollment, with some comparison
175	arm participants later enrolling in DSD and some never doing so. To mimic this in our emulated trial, we
176	assigned anyone within the baseline enrollment period who did not enroll in DSD to the comparison
177	arm, noting that after baseline, they had regular standard care, which in some cases could involve later
178	enrolling in DSD.
179	
180	Development of multiple trial emulations
181	
182	For this analysis, we chose to emulate a series of eight target trials, each encompassing a 6-calendar
183	month DSD enrollment period in our data set as our baseline, between 1 July 2017 and 1 Jul 2021 (e.g. 1
184	July 2017 to 31 December 2017, 1 January 2018 to 30 June 2018, etc.). This approach maximized the
185	value of our multi-year data set within the constraints of the target trial methodology. Had we
186	conducted only one emulated trial limited to the first six-month calendar period for which we had data
187	(July to December 2017), all participants could readily have been assigned to either intervention or
188	comparison arm status, but this approach would have excluded all the individuals in the data set who
189	enrolled in or became eligible for DSD enrollment after December 2017. Alternatively, we could have
190	conducted only one emulated trial incorporating all the data in our data set (July 2017 to June 2021), in
191	which all clients who enrolled in DSD later in the study period would have been assigned to the DSD
192	arm. As those clients would, by definition, have survived longer on ART before enrolling in DSD,
193	however, and longer duration on ART is associated with better retention and suppression outcomes, this
194	could create bias.

196 Emulating multiple, time-limited trials offers one solution to the problem described above. Within each 197 of the eight target trial periods we assessed eligibility for participation in the trial and DSD models for 198 individuals in the database at the start of each six-month trial (Figure 1). All those who met the criteria 199 were included in the new trial, and individual clients could thus be included in the comparison arm of 200 multiple trials. Participants eligible for each six-month calendar period were then assigned to the 201 intervention or comparison arm. Because being DSD-naïve is a trial eligibility criterion, anyone who had 202 enrolled in DSD during a prior six-month period and been analyzed in a previous emulated trial would no 203 longer be eligible for subsequent trials. A participant who had not yet enrolled in DSD in a prior period 204 could meet the study eligibility criteria for subsequent trials, however, along with anyone who became 205 newly eligible for DSD based on national guidelines. As a result, any individual could be enrolled in one 206 or more trials as a comparison arm participant only; in one or more trials as a comparison arm 207 participant and one as an intervention participant; or in just one trial as an intervention participant. 208

209 Figure 1: Summary of the eight target trial periods



211 Outcomes

212

213 We defined two outcomes for this analysis, retention in care and viral suppression, each assessed at 12, 214 24, and 36 months after the start date of follow-up as specified in Table 2. Retention in care was defined 215 as having had a recorded clinic visit at the same clinic facility at 12, 24, or 36 months after the start date, 216 with the start date defined as the DSD enrolment date for the intervention arm and the first clinic visit 217 attended during the trial enrolment period for the comparison arm. Viral suppression (<400 copies/mL) 218 was also assessed at these time points but could only be reported for those with viral loads measured 219 (i.e. our denominator only includes those who had documented viral load results in their medical 220 records); participants missing viral load measures were excluded from the analysis of this second 221 outcome. It is important to note that because our data source, TIER.Net, does not capture unreported 222 ("silent") transfers between facilities, those who informally transfer appear to have disengaged from 223 care. Retention in this study thus refers to retention at the same facility, not retention across the HIV 224 treatment program.

225

226 For both retention in care and viral suppression outcomes, we allowed for a wide 12-month window 227 after the endpoint to recognize outcomes. Clients were considered retained in care for 12 months, for 228 example, if they had a clinic visit any time between 12 and 24 months after DSD enrolment, and their 229 viral load outcome for the 12-month endpoint reflected laboratory tests conducted between 12 and 24 230 months after DSD enrollment. These relatively long (12-month) windows were chosen to accommodate 231 local practice during the study period, which included the COVID-19 pandemic when South Africa 232 temporarily allowed 12-month prescriptions of ART medications. A 12-month window for recording viral 233 suppression was necessary because viral load tests are recommended and typically conducted only 234 every 12 months after the first year on ART. We used the earliest viral load result within the 12-month 235 window after the specified endpoint as the outcome measure. We also extracted from TIER.Net 236 individual characteristics such as age, gender, time on ART, WHO stage, and CD4 count at ART initiation.

\mathbf{a}	2	7
7	Э	1

238	Follow-up for all clients continued for up to 48 months from the start date through their electronic
239	medical records in the TIER.Net system. We applied administrative censoring for each 12-, 24- and 36-
240	month outcome to ensure clients had sufficient potential follow-up data available to assess outcomes.
241	Clients were censored if the outer window for measuring each outcome went beyond the data
242	extraction date. For assessing the 12-month outcome, for example, clients included in the analysis had
243	to have at least 24 months of potential follow-up data available (= 12-month follow up period + 12-
244	month window for outcomes). Clients starting in 2021 or later had not accrued enough follow-up time
245	for the 24- and 36-month outcomes. These clients were excluded from having their outcomes assessed
246	at 24 and/or 36 months and are denoted as having "insufficient follow-up" for those time points.
247	
248	Statistical analysis
249	
250	We first describe the characteristics of the unique clients in the analytic cohort in the study. Since
251	individual participants could be included in multiple trials, however, our unit of analysis was a trial-
252	client, rather than a unique client. Trial-clients are also described (supplementary files). Once all eight
253	target trials were defined and the cohorts were created, we estimated the risk differences for retention
254	in care and viral suppression comparing those in DSD to those not enrolled in DSD models using a
255	Poisson distribution with an identity link function. We adjusted for age, gender, urban/rural setting,
256	province, WHO stage at ART initiation, and years on ART at trial enrolment. We did not adjust for CD4
257	count at ART initiation for two reasons: 1) potential collinearity with WHO stage and 2) CD4 count had
258	more missing data compared to WHO stage. We did conduct a sensitivity analysis in which we adjusted
259	for CD4 count at ART initiation in place of WHO stage, and these results are reported in the
260	Supplementary Appendix. We also conducted an age-stratified and sex-stratified analysis to further

261	evaluate the age- and sex-specific impact of DSD on health outcomes. We present risk differences and
262	95% confidence intervals for each of the eight trials and a pooled estimate that further adjusts for the
263	individual target trial. To account for clients appearing in multiple target trials (resulting in multiple trials
264	for some that would artificially inflate the sample size and bias our standard errors), we also adjusted for
265	within-subject variance using robust variance estimates.
266	
267	Ethics approval
268	
269	The study was approved by the Human Research Ethics Committee (HREC) of the University of the
270	Witwatersrand (M190445) and the Boston University Institutional Review Board (IRB) (H-38115). Both
271	approved use of routine clinic data for the evaluation and provided a waiver of consent.
272	
273	Results
274	
275	Analytic cohort
276	
277	A total of 49,595 unique individuals were eligible for DSD model enrolment in our data set. Of these,
278	52% (25,775) were enrolled in DSD models during the observation period, while 23,820 were eligible but
279	never enrolled. The distribution of gender and WHO stage at ART initiation was similar between those
280	ever enrolled in DSD and those who remained in standard care, with two-thirds (67%) of the clients in
281	WHO stage 1 at baseline and most (69%) female (Table 3). The age and median time on ART at the start
282	of the first trial were higher for those enrolled in DSD (51% aged 35-49 years; median time on ART 4.0
283	years [interquartile range (IQR) 2.3 to 6.5 years]) compared to those not enrolled in DSD (42% aged 35-

- were less likely to be enrolled in DSD than were older clients. Clients ever enrolled in DSD were slightly
- more likely to receive care in urban settings than were those never enrolled in DSD (75% vs 69%,
- respectively) (Table 3). Cohort characteristics based on client trials, rather than unique individuals
- 288 (available in Supplementary Table S2), are more balanced between DSD and our comparator arms.
- 289

291

290 Table 3. Characteristics of cohort eligible for DSD models in the study

Characteristic		Number of	Never enrolled in DSD	Ever enrolled in DSD (%)
		clients	(%)	
		(% of total)		
N		49,595	23,820	25,775
Age group in years	18-24	2,759 (6%)	1,868 (68%)	891 (32%)
	25-34	14,715 (30%)	7,625 (52%)	7,090 (48%)
	35-49	23,064 (47%)	10,040 (44%)	13,024 (56%)
	50+	9,057 (18%)	4,287 (47%)	4,770 (53%)
Gender	Female	34,145 (69%)	16,273 (48%)	17,872 (52%)
	Male	15,450 (31%)	7,547 (49%)	7,903 (51%)
Years on ART at trial start	Years (median, IQR)	3.3 (1.8 – 6.0)	2.5 (1.5 - 5.3)	4.0 (2.3 - 6.5)
	1 to <2	14,249 (29%)	9,333 (65%)	4,916 (35%)
	2 to <5	18,881 (38%)	7,897 (42%)	10,984 (58%)
	5+	16,465 (33%)	6,590 (40%)	9,875 (60%)
WHO stage at ART initiation	1	30,022 (67%)	14,473 (48%)	15,549 (52%)
	2	8,105 (18%)	3,801 (47%)	4,304 (53%)
	3	5,582 (13%)	2,576 (46%)	3,006 (54%)
	4	861 (2%)	409 (48%)	452 (52%)
CD4 (cells/µl) at ART initiation	n; median (IQR)	244 (131 - 386)	250 (133 - 407)	239 (129 - 370)
Location	Rural	13,685 (28%)	7,289 (53%)	6,396 (47%)
	Urban	35,910 (72%)	16,531 (46%)	19,379 (54%)
Province	Gauteng	23,833 (48%)	11,145 (47%)	12,688 (53%)
	KwaZulu-Natal	12,193 (25%)	6,696 (55%)	5,497 (45%)
	Mpumalanga	13,569 (27%)	5,979 (44%)	7,590 (56%)

²⁹²

²⁹³ As explained above, because individual participants were included in multiple trials, our unit of analysis 294 was a trial-client, rather than a unique client. 580,276 trial-clients were assessed over the eight target 295 trial enrolment periods between July 2017 and July 2021 (Figure 2). Of all trial-clients, 431,333 were 296 excluded for different reasons: a third (34%, n=200,125) were previously exposed to DSD models, 5% 297 (n=27,791) had not had a recent clinic visit before trial enrolment, 3% (n=18,695) were aged <18 years, 298 2% (n=9,623) were pregnant during the trial enrolment period, 16% (n=69,136) had <12 months of ART 299 experience, and 25% (n=105,963) were not virally suppressed (Figure 2). A detailed disaggregated flow 300 diagram depicting each of the eight target trials is available in Supplementary Figure S1.

301 Figure 2: Flow diagram, consolidated across all eight target trials





Figure 3: (A) Retention in care and (B) viral load suppression outcomes by DSD enrolment, at 12, 24,



316



317 The pooled adjusted risk difference for retention in care between clients enrolled in DSD and those 318 eligible but not enrolled was estimated to be 3.2% (95% confidence interval (CI) 1.6%; 4.7%) at 12 319 months, 4.2% (2.4%; 6.0%) at 24 months, and 4.4% (2.0%; 6.8%) at 36 months (Figure 4). Estimates 320 stratified by each of the target trials were similar, except for the 12-month outcome in the 7th trial which 321 could be explained by timing of the trial enrolment period, which occurred during the first two waves of 322 the COVID-19 pandemic. 323 For viral suppression outcomes, the adjusted risk difference comparing DSD to non-DSD was estimated 324 to be 1.4% (-0.5%; 3.2%) at 12 months, 1.7% (-0.5%; 4.0%) at 24 months, and 1.4% (-0.6%; 4.4%) at 36 325 months (Figure 5). The pooled adjusted risk differences including the covariate estimates are available in 326 Supplementary Table S3. These show that clients who were younger (aged 18-34 years), received care 327 from an urban clinic, or had fewer years on ART (<2 years) at study enrolment were significantly less 328 likely to be retained in care, while those aged 18-24 years had lower rates of viral suppression at 12 329 months (Supplementary Table S3). Adjusting for CD4 count at ART initiation, instead of WHO stage, did 330 not fundamentally change the effect estimates for those on DSD models (Supplementary Table S4).

331	Age-stratified analyses showed some variation in risk difference estimates between age groups when
332	comparing DSD vs non-DSD rates of retention and viral suppression. In particular, younger participants
333	(aged 18-24 years) had a higher risk difference for both retention and viral suppression compared to
334	those older (aged 25+ years) (Supplementary Table S5 and S6). Adjusted risk differences for retention
335	ranged from 4.4%-7.8% for 18-24-year-old clients and from 2.5%-5.4% for clients aged 25+ years, while
336	for viral suppression they ranged from 3.3%-6.1% (aged 18-24 years) and from 0.9%-1.7% (aged 25+
337	years). Confidence intervals were wider for 18-24-year-old clients due to the smaller sample sizes
338	involved, however. Sex-stratified analyses produced similar risk difference estimates between males and
339	females for retention. There were some differences in viral suppression by sex, however, with male
340	clients having a slightly higher adjusted risk difference estimate comparing DSD vs non-DSD (ranging
341	from 1.8%-2.2%) than did female clients (range 1.1%-1.5%) (Supplementary Table S7 and S8).
342 343 344	

- 345Figure 4: Adjusted risk differences for retention in care (12, 24, and 36 months) comparing DSD vs346non-DSD clients
- 347





○ Unadjusted ● Adjusted



Figure 5: Adjusted risk differences for viral suppression (12, 24, and 36 months) comparing DSD vs non-DSD clients

- 555 1
- 354

355 356 357

358



359 In this study, we conducted one of the first analyses of a large cohort of clients comparing viral

- 360 suppression and retention outcomes between those enrolled in differentiated service delivery models
- 361 and those eligible for DSD enrollment but remaining in conventional care in a routine healthcare setting.

We found that clients enrolled in DSD models had similar or slightly better rates of retention in care and
 viral load suppression as did those who were eligible for DSD but remained in conventional care.

364

365 For clients eligible for DSD—i.e. those considered "established" on ART-- it is reassuring that retention 366 and suppression outcomes were comparable between conventional care and DSD models. There was 367 little room for these clients' rate of viral suppression to improve over the follow-up period, as all had 368 documented viral suppression at enrollment. The concern that less intensive models of service delivery, 369 with less direct interaction with clients than under conventional care, might lead to worse retention in 370 care, however, was not borne out in our analysis. The potential benefits of differentiated service 371 delivery, in this setting, can thus be assessed based on non-clinical factors, such as costs to clients, 372 health system resource utilization and efficiency, and client and provider satisfaction. 373 374 While countries across sub-Saharan Africa have implemented differentiated models of HIV treatment, 375 few of these programs have undergone rigorous evaluation at scale. Many studies have focused on the 376 impact of individual interventions, often in controlled settings, while less attention has been given to 377 reporting outcomes of these DSD models in routine care settings after national implementation. Despite 378 differences in study designs, our results largely align with the majority of studies on individual models, 379 indicating that less intensive DSD models enrolling clients already established on ART provide equivalent 380 or slightly better retention and viral suppression outcomes [11-17]. Our findings are also consistent with 381 a recent large-scale study assessing the impact of DSD models on 12-month retention in 382 Mozambique[24]. In that study, the research team conducted an interrupted time series analysis 383 comparing clinic-wide retention before and 12 months after the implementation of a package 384 comprising eight models of care. We note that while the question of clinic-wide retention addressed in

385 that analysis differs from the one addressed in our paper, which specifically focuses on the eligible 386 population, both perspectives merit consideration.

387

388 Our study had several limitations, most resulting from the observational design and reliance on routinely 389 collected medical records. Although the use of TIER.Net data provided a large sample of ART clients 390 attending multiple healthcare facilities, until June 2020 it did not record the specific DSD model in which 391 a client was enrolled and instead only captured whether the client was in a DSD model or not. As noted 392 above, TIER.Net does not capture off-site medication collection visits for clients enrolled in DSD models, 393 but only the facility-based visits that occur every 6 months, requiring a long follow-up window for 394 retention to be documented. Since the TIER.Net system is not linked across facilities, moreover, "silent" 395 or unrecorded transfers between facilities appear in the system as disengagement from care, likely 396 underestimating overall retention in this study. We cannot know if this effect is differential or non-397 differential between DSD and comparison clients, however. In addition, in South Africa, the CCMDD 398 program, which provides the majority of medication for DSD models, requires a valid South African 399 identification number, passport number, or asylum seeker number for registration. Anecdotally, a lack 400 of a valid identification number for registration is often offered as a reason for not enrolling clients in 401 the CCMDD program. In clinics with a large number of individuals without these numbers, such as those 402 that serve immigrant communities, facilities may decide to pack medications themselves, at the facility, 403 rather than relying on the CCMDD program. This could explain why some clients who appear in their 404 medical records to be eligible for DSD are not enrolled.

405

406 The target trial emulation methodology used in this analysis is a robust method for defining a

407 comparator arm and determining outcomes in routine care data but it cannot correct all issues that

408 affect observational studies. It can help prevent issues like misaligned person time, poorly defined

409	eligibility criteria, and unclear causal questions. It does not fully address the limitations of observational
410	studies, however, as residual confounding can still be present. In our case, it is likely that many of those
411	who were offered and accepted enrollment in DSD models were, on average, in better health, more
412	motivated, or more empowered to remain in care than those who were not, suggesting that DSD
413	participants may have had better outcomes than comparison participants even in the absence of DSD.
414	This bias would overestimate the retention benefit of DSD over conventional care. The exclusion from
415	DSD of otherwise-eligible clients without national identification numbers could also skew our results,
416	either in favor of no difference (if clients without ID numbers also have good outcomes in conventional
417	care, offsetting the bias mentioned above) or by overestimating the effect of DSD, if clients without ID
418	numbers face greater barriers to remaining in care.
419	
420	Despite these study limitations, our results using a robust observational methodology and large sample
421	size suggest that retention and viral suppression for those in DSD models in South Africa are similar to,
422	or better than, outcomes in conventional care for ART clients who meet typical DSD eligibility criteria.
423	These findings should assure policy makers and program managers that the less intensive models of care
424	that South Africa has introduced do not threaten the achievements of national HIV programs and that
425	the non-clinical benefits they generate for the healthcare system, such as savings in provider time use,
426	and for clients, such as less time and lower costs, will not be offset by poorer clinical outcomes.
427	
428	Competing interests
429	
430	The authors have no competing interests to report. LM, MM and NK are employed by the government
431	agency that has supervisory authority over the healthcare facilities from which the data for this study
432	were drawn.
433	
434	Authors' contributions
435	
436	Conceptualization: Amy Huber, Lise Jamieson, Matthew Fox, Brooke Nichols, Sydney Rosen
437	Data curation: Amy Huber, Lise Jamieson

438	Forma	ıl analysis: Amy Huber, Lise Jamieson, Matthew Fox					
439	Funding acquisition: Sophie Pascoe, Sydney Rosen						
440	Methodology: Matthew Fox, Lise Jamieson						
441	Project administration: Amy Huber, Sophie Pascoe						
442	Validation: Lufuno Malala, Musa Manganye, Thato Chidarikire, Nthabiseng Khoza						
443	Visualization: n/a						
444	Writin	g – original draft: Amy Huber, Lise Jamieson, Sydney Rosen					
445	Writin	g – review & editing: Amy Huber, Lise Jamieson, Matthew P. Fox, Musa Manganye, Lufuno Malala					
446	Thato	Chidarikire Nthahiseng Khoza Brooke Nichols Sydney Rosen Sonhie Pascoe					
447	mato						
117	Fundi	ng					
770 //Q	runun	'5					
44)	Eundir	ag for the study was provided by the Pill & Melinda Cates Foundation through OPD1102640 to					
450	Pacto	Ig for the study was provided by the Bill & Melinua Gates Foundation through OPP1192040 to					
451	BOSTO	n University and INV-037138 to the Wits Health Consortium. The funders had no role in study					
452	design	i, data conection and analysis, decision to publish of preparation of the manuscript.					
433	Defen						
454	Refere	ences					
455							
456	1.	Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in sub-					
45/		Saharan Africa during COVID-19. J Int AIDS Soc. 2021;24: e25704. doi:10.1002/jia2.25704					
458	_						
459	2.	Ehrenkranz P, Grimsrud A, Rabkin M. Differentiated service delivery: Navigating the path to scale.					
460		Curr Opin HIV AIDS. 2019;14: 60–65. doi:10.1097/COH.00000000000000509					
461							
462	3.	Duncombe C, Rosenblum S, Hellmann N, Holmes CB, Wilkinson L, Biot M, et al. Reframing HIV					
463		care: putting people at the centre of antiretroviral delivery. Trop Med Int Health. 2015;20: n/a-					
464		n/a. doi:10.1111/tmi.12460					
465							
466	4.	Ehrenkranz P, Grimsrud A, Holmes C, Preko P, Rabkin M. Expanding the vision for differentiated					
467		service delivery: a call for more inclusive and truly patient-centered care for people living with					
468		HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2020;Publish Ah: 147–152.					
469		doi:10.1097/QAI.000000000002549					
470							
471	5.	Huber A, Pascoe S, Nichols B, Long L, Kuchukhidze S, Phiri B, et al. Differentiated Service Delivery					
472		Models for HIV Treatment in Malawi. South Africa, and Zambia: A Landscape Analysis. Glob					
473		Health Sci Pract. 2021:9.					
474							
475	6	HIV Coverage, Quality, and Impact Network (COUIN), COUIN 7th Annual Meeting Posters, COUIN					
476	0.	7th Annual Meeting: November 13–17, 2023: Johannesburg, South Africa, Available from:					
477		https://cauja ican columbia edu/event/cauja-7th-annual-meeting/nosters/					
478		https://equinicap.columbia.cou/event/equin / in annual meeting/posters/					
470 //79	7	World Health Organization, Latest HIV estimates and undates on HIV policies untake. Global HIV					
480	/.	Henatitis and STI Programmes 2020: 1-40 Available: https://www.who.int/docs/dofault					
-100 /181		source/hiv-ba/latest-hiv-estimates-and undates on hiv policies untake					
401		november2020 ndf2sfyrsn=1020042d 12					
+02 182		110ve1110e12020.pu1:51v1511-10a0045U_12					
403							

484 485 486	8.	The South African National Department of Health. Adherence Guidelines for HIV, TB and NCDs. Department of Health, Pretoria, Republic of South Africa; 2023.
480 487 488 489 490	9.	Liu L, Christie S, Munsamy M, Roberts P, Pillay M, Shenoi S V, et al. Expansion of a national differentiated service delivery model to support people living with HIV and other chronic conditions in South Africa : a descriptive analysis. BMC Health Serv Res. 2021;21: 463.
491 492 493 494 495	10.	Dorward J, Msimango L, Gibbs A, Shozi H, Tonkin-Crine S, Hayward G, et al. Understanding how community antiretroviral delivery influences engagement in HIV care: A qualitative assessment of the Centralised Chronic Medication Dispensing and Distribution programme in South Africa. BMJ Open. 2020;10. doi:10.1136/bmjopen-2019-035412
496 497 498 499 500	11.	Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8: e56088. doi:10.1371/journal.pone.0056088
500 501 502 503 504	12.	Wang M, Violette LR, Dorward J, Ngobese H, Sookrajh Y, Bulo E, et al. Delivery of Community- based Antiretroviral Therapy to Maintain Viral Suppression and Retention in Care in South Africa. J Acquir Immune Defic Syndr. 2023 Jun 1;93(2):126-133. doi: 10.1097/QAI.000000000003176.
505 506 507 508	13.	Lewis L, Sookrajh Y, Van Der Molen J, Khubone T, Maraj M, Sosibo P, et al. Long-term usage patterns and clinical outcomes in a community-based differentiated antiretroviral therapy delivery programme in South Africa. J Int AIDS Soc. 2023;26: 26141. doi:10.1002/jia2.26141/full
509 510 511 512	14.	Long L, Kuchukhidze S, Pascoe S, Nichols BE, Fox MP, Cele R, et al. Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic review. J Int AIDS Soc. 2020;23: 1–14. doi:10.1002/jia2.25640
512 513 514 515 516 517	15.	Fox MP, Pascoe S, Huber AN, Murphy J, Phokojoe M, Gorgens M, et al. Adherence Clubs and Decentralized Medication Delivery to Support Patient Retention and Sustained Viral Suppression in Care: Results from A Cluster Randomized Evaluation of Differentiated ART delivery models in South Africa. PLoS Med. 2019;16: e1002874.
517 518 519 520 521	16.	Jo Y, Jamieson L, Phiri B, Grimsrud A, Mwansa M, Shakwelele H, et al. Attrition from HIV treatment after enrollment in a differentiated service delivery model: A cohort analysis of routine care in Zambia. PLoS One. 2023;18: e0280748. doi:10.1371/journal.pone.0280748
522 523 524 525 526	17.	Uetela DAM, Augusto O, Hughes JP, Uetela OA, Gudo ES, Chicumbe SA, et al. Impact of differentiated service delivery models on 12-month retention in HIV treatment in Mozambique: an interrupted time-series analysis. Lancet HIV. 2023;10: e674–e683. doi:10.1016/S2352- 3018(23)00184-4
527 528 529 530	18.	The South African National Department of Health. Adherence guidelines for HIV, TB and NCDs: Policy and service guidelines for linkage to care, adherence to treatment and retention in care. Department of Health, Pretoria, Republic of South Africa; 2016.

531 532 533 534 535	19.	Pascoe S, Huber A, Mokhele I, Lekodeba N, Ntjikelane V, Sande L, et al. The SENTINEL study of differentiated service delivery models for HIV treatment in Malawi, South Africa, and Zambia: research protocol for a prospective cohort study. BMC Health Serv Res. 2023;23: 891. doi:10.1186/s12913-023-09813-w
536 537 538 539	20.	Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17. doi:10.7448/IAS.17.1.18908
540 541 542 543 544	21.	Etoori D, Wringe A, Kabudula CW, Renju J, Rice B, Gomez-Olive FX, et al. Misreporting of Patient Outcomes in the South African National HIV Treatment Database: Consequences for Programme Planning, Monitoring, and Evaluation. Front Public Health. 2020;8. doi:10.3389/FPUBH.2020.00100
545 546 547	22.	Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183: 758–764. doi:10.1093/aje/kwv254
548 549 550 551	23.	Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79: 70–75. doi:10.1016/j.jclinepi.2016.04.014
552 553 554 555 556	24.	Uetela DAM, Augusto O, Hughes JP, Uetela OA, Gudo ES, Chicumbe SA, et al. Impact of differentiated service delivery models on 12-month retention in HIV treatment in Mozambique: an interrupted time-series analysis. Lancet HIV. 2023;10: e674–e683. doi:10.1016/S2352-3018(23)00184-4

Supplementary Appendix

Table S1. Study site description

Site	Setting	Number on ART 2021	Approximate % of ART clients enrolled in DSD models (2021)						
Ekurhuleni District (data from Jan 2016 - Jun 2020)									
Clinic	Urban	2,386	53%						
Clinic	Urban	2,658	44%						
Clinic	Urban	7,213	51%						
Clinic	Urban	1,482	Missing						
Clinic	Urban	3,502	Missing						
Clinic	Urban	4,560	Missing						
West Rand District (data from Jan 2016	5 - Jun 202 <mark>3)</mark>								
Clinic	Urban	1,783	Missing						
Clinic	Rural	1,803	32%						
Clinic	Urban	1,897	24%						
Clinic	Urban	2,116	57%						
Clinic	Rural	2,301	43%						
Clinic	Urban	2,959	66%						
Ehlanzeni District (data from Jan 2016	- Jan 2023)								
Community Health Centre	Urban	6,622	61%						
Clinic	Rural	3,553	44%						
Clinic	Rural	1,943	48%						
Clinic	Rural	3,001	11%						
Community Health Centre	Urban	5,234	25%						
Clinic	Urban	5,515	28%						
King Cetshwayo District (data from Jan	2016 - Apr 20)23)							
Clinic	Rural	1,182	24%						
Clinic	Rural	1,509	81%						
Clinic	Rural	2,231	78%						
Clinic	Rural	3,361	Missing						
Clinic	Rural	5,190	61%						
Clinic	Urban	7,934	75%						

6 Figure S1. Cohort flow diagram



10 Figure S1. Cohort flow diagram (continued)





14 Table S2. Baseline demographics of trial-clients eligible for DSD models across all eight emulated target trials

1	5
_	-

			Not enrolled in	
		Total (%)	DSD (%)	Enrolled in DSD (%)
Number of trial-clients *		148,943	123,168	25,775
Age group in years	18-24	6,664 (4%)	5,773 (87%)	891 (13%)
	25-34	40,063 (27%)	32,973 (82%)	7,090 (18%)
	35-49	70,700 (47%)	57,676 (82%)	13,024 (18%)
	50+	31,516 (21%)	26,746 (85%)	4,770 (15%)
Gender	Female	102,680 (69%)	84,808 (83%)	17,872 (17%)
	Male	46,263 (31%)	38,360 (83%)	7,903 (17%)
Years on ART at trial start,		(/	/
median (IQR)		4.1 (2.4 - 6.7)	4.1 (2.4 - 6.7)	4.0 (2.3 - 6.5)
Years on ART at trial start	1-<2	26,590 (18%)	21,674 (82%)	4,916 (18%)
	2-<5	62,539 (42%)	51,555 (82%)	10,984 (18%)
	5+	59,814 (40%)	49,939 (83%)	9,875 (17%)
WHO stage at ART initiation	1	86,361 (65%)	70,812 (82%)	15,549 (18%)
	2	25,732 (19%)	21,428 (83%)	4,304 (17%)
	3	17,901 (13%)	14,895 (83%)	3,006 (17%)
	4	2,842 (2%)	2,390 (84%)	452 (16%)
CD4 (cells/µl) at ART initiation	n; median (IQR)	238 (128 - 371)	237 (128 - 372)	239 (129 - 370)
Location	Rural	42,292 (28%)	35,896 (85%)	6,396 (15%)
	Urban	106,651 (72%)	87,272 (82%)	19,379 (18%)
Province	Gauteng	71,265 (48%)	58,577 (82%)	12,688 (18%)
	KwaZulu-Natal	37,327 (25%)	31,830 (85%)	5,497 (15%)
	Mpumalanga	40,351 (27%)	32,761 (81%)	7,590 (19%)

16 * trial-clients refers to the number of clients followed across all 8 target trials, with some clients appearing in multiple target trials

		Retained/N (%)	Retention in care Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)	Virally suppressed/N* (%)	Viral suppression Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)
12 months							
DSD enrolment	No	93,966/103,786 (91%)	reference	reference	74,108/77,643 (95%)	reference	reference
	Yes	18,583/19,881 (93%)	2.9 (1.5; 4.4)	3.2 (1.6; 4.7)	14,824/15,320 (97%)	1.3 (-0.4; 3.0)	1.4 (-0.5; 3.2)
Age group (years)	18-24	5,010/5,883 (85%)	-7.3 (-9.7; -4.7)	-7.1 (-9.8; -4.4)	3,788/4,096 (92%)	-3.6 (-6.6; -0.4)	-3.8 (-7.1; -0.4)
	25-34	30,506/34,203 (89%)	-3.2 (-4.5; -1.9)	-2.9 (-4.3; -1.5)	23,878/25,100 (95%)	-0.9 (-2.4; 0.6)	-1.1 (-2.8; 0.5)
	35-49	53,175/57,542 (92%)	reference	reference	42,307/44,051 (96%)	reference	reference
	50+	23,858/26,039 (92%)	-0.8 (-2.2; 0.6)	-0.8 (-2.3; 0.7)	18,959/19,716 (96%)	0.1 (-1.5; 1.8)	0.3 (-1.5; 2.1)
Gender	Female	78,225/85,960 (91%)	reference	reference	62,330/64,863 (96%)	reference	reference
	Male	34,324/37,707 (91%)	0.0 (-1.1; 1.2)	-0.4 (-1.7; 0.8)	26,602/28,100 (95%)	-1.4 (-2.8; -0.1)	-1.6 (-3.1; -0.1)
Location	Rural	38,137/41,278 (92%)	reference	reference	29,723/31,548 (94%)	reference	reference
	Urban	74,412/82,389 (90%)	-2.1 (-3.2; -0.9)	-2.1 (-3.6; -0.6)	59,209/61,415 (96%)	2.2 (0.9; 3.5)	1.0 (-0.7; 2.8)
Province	GP	42,750/47,423 (90%)	reference	reference	33,615/34,716 (97%)	reference	reference
	KZN	33,793/37,065 (91%)	1.0 (-0.3; 2.3)	0.5 (-1.0; 2.1)	28,242/29,365 (96%)	-0.7 (-2.2; 0.9)	0.1 (-1.8; 1.9)
	MP	36,006/39,179 (92%)	1.8 (0.5; 3.0)	0.4 (-1.3; 2.1)	27,075/28,882 (94%)	-3.1 (-4.6; -1.6)	-2.2 (-4.2; -0.2)
Years on ART	1-<2	20,108/22,711 (89%)	-3.8 (-5.3; -2.3)	-2.8 (-4.4; -1.1)	16,016/16,806 (95%)	-0.6 (-2.4; 1.2)	-0.2 (-2.2; 1.8)
	2-<5	47,995/52,818 (91%)	-1.5 (-2.6; -0.3)	-0.8 (-2.1; 0.5)	37,571/39,298 (96%)	-0.3 (-1.7; 1.1)	-0.1 (-1.6; 1.4)
	5+	44,446/48,138 (92%)	reference	reference	35,345/36,859 (96%)	reference	reference
WHO stage at ART	1	63,847/70,449 (91%)	reference	reference	50,763/52,704 (96%)	reference	reference
initiation	2	19,731/21,506 (92%)	1.1 (-0.3; 2.6)	0.4 (-1.1; 1.9)	15,353/16,185 (95%)	-1.5 (-3.2; 0.3)	-1.1 (-2.9; 0.6)
	3	13,060/14,339 (91%)	0.5 (-1.3; 2.2)	-0.3 (-2.1; 1.4)	10,235/10,829 (95%)	-1.8 (-3.8; 0.2)	-1.9 (-4.0; 0.1)
	4	2,048/2,256 (91%)	0.2 (-3.8; 4.2)	-0.6 (-4.5; 3.5)	1,634/1,731 (94%)	-1.9 (-6.5; 2.8)	-2.2 (-6.8; 2.5)
24 months							
DSD enrolment	No	61,943/72,788 (85%)	reference	reference	48,637/51,107 (95%)	reference	reference
	Yes	12,203/13,733 (89%)	3.8 (2.1; 5.5)	4.2 (2.4; 6.0)	9,943/10,241 (97%)	1.9 (-0.2; 4)	1.7 (-0.5; 4.0)
Age group (years)	18-24	3,102/4,031 (77%)	-10.7 (-13.6; -7.9)	-10.7 (-13.8; -7.5)	2,342/2,551 (92%)	-4.2 (-8.0; -0.3)	-4.2 (-8.4; 0.2)
	25-34	20,214/24,142 (84%)	-4.0 (-5.4; -2.5)	-3.6 (-5.2; -2.0)	15,752/16,652 (95%)	-1.4 (-3.3; 0.4)	-1.6 (-3.6; 0.5)
	35-49	35,234/40,178 (88%)	reference	reference	28,080/29,248 (96%)	reference	reference
	50+	15,596/18,170 (86%)	-1.9 (-3.5; -0.2)	-1.8 (-3.6; 0.0)	12,406/12,897 (96%)	0.2 (-1.8; 2.2)	0.4 (-1.8; 2.7)
Gender	Female	51,960/60,536 (86%)	reference	reference	41,421/43,186 (96%)	reference	reference
	Male	22,186/25,985 (85%)	-0.5 (-1.8; 0.9)	-1.1 (-2.5; 0.4)	17,159/18,162 (94%)	-1.4 (-3.1; 0.3)	-1.4 (-3.2; 0.5)
Location	Rural	26,638/30,270 (88%)	reference	reference	20,544/21,884 (94%)	reference	reference
	Urban	47,508/56,251 (84%)	-3.5 (-4.8; -2.2)	-3.3 (-5.0; -1.5)	38,036/39,464 (96%)	2.5 (0.9; 4.1)	1.1 (-1.1; 3.2)
Province	GP	24,846/29,616 (84%)	reference	reference	19,713/20,294 (97%)	reference	reference
	KZN	23,537/27,290 (86%)	2.4 (0.8; 3.9)	1.7 (-0.1; 3.5)	19,762/20,596 (96%)	-1.2 (-3.1; 0.7)	-0.4 (-2.6; 1.9)
	MP	25,763/29,615 (87%)	3.1 (1.6; 4.6)	1.3 (-0.6; 3.2)	19,105/20,458 (93%)	-3.8 (-5.6; -1.9)	-2.7 (-5.1; -0.2)
Years on ART	1-<2	13,513/16,314 (83%)	-4.5 (-6.3; -2.8)	-3.5 (-5.5; -1.6)	10,648/11,197 (95%)	-0.9 (-3.1; 1.3)	-0.4 (-2.9; 2.1)
	2-<5	32,288/37,761 (86%)	-1.9 (-3.2; -0.5)	-1.1 (-2.7; 0.4)	25,282/26,561 (95%)	-0.8 (-2.5; 0.9)	-0.6 (-2.5; 1.3)
	5+	28,345/32,446 (87%)	reference	reference	22,650/23,590 (96%)	reference	reference
WHO stage at ART	1	40,646/47,719 (85%)	reference	reference	32,427/33,686 (96%)	reference	reference
initiation	2	13,533/15,646 (86%)	1.3 (-0.4; 3.0)	0.3 (-1.4; 2.0)	10,456/11,065 (94%)	-1.8 (-3.9; 0.3)	-1.4 (-3.5; 0.8)

18 Table S3. Pooled adjusted risk difference (%) of retention in care and viral suppression by DSD enrolment at 12, 24 and 36 months

		Retained/N (%)	Retention in care Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)	Virally suppressed/N* (%)	Viral suppression Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)
	3	8,712/10,182 (86%)	0.4 (-1.6; 2.4)	-0.5 (-2.5; 1.5)	6,847/7,255 (94%)	-1.9 (-4.3; 0.6)	-2.1 (-4.6; 0.4)
	4	1,376/1,583 (87%)	1.7 (-2.8; 6.5)	0.8 (-3.8; 5.5)	1,107/1,172 (94%)	-1.8 (-7.4; 4.0)	-2.2 (-7.7; 3.6)
36 months							
DSD enrolment	No	33,568/41,512 (81%)	reference	reference	26,481/27,735 (95%)	reference	reference
	Yes	6,810/8,015 (85%)	4.1 (1.9; 6.3)	4.4 (2.0; 6.8)	5,635/5,807 (97%)	1.6 (-1.2; 4.4)	1.4 (-1.6; 4.4)
Age group (years)	18-24	1,679/2,351 (71%)	-12.4 (-16.0; -8.7)	-12.0 (-16.0; -8.0)	1,273/1,372 (93%)	-3.3 (-8.6; 2.1)	-3.5 (-9.3; 2.4)
	25-34	11,162/13,950 (80%)	-3.8 (-5.7; -1.9)	-3.4 (-5.5; -1.3)	8,792/9,259 (95%)	-1.2 (-3.6; 1.4)	-1.1 (-3.9; 1.7)
	35-49	19,090/22,773 (84%)	reference	reference	15,356/15,978 (96%)	reference	reference
	50+	8,447/10,453 (81%)	-3.0 (-5.1; -0.9)	-2.9 (-5.2; -0.6)	6,695/6,933 (97%)	0.5 (-2.3; 3.2)	0.5 (-2.5; 3.6)
Gender	Female	28,593/34,875 (82%)	reference	reference	23,010/23,910 (96%)	reference	reference
	Male	11,785/14,652 (80%)	-1.6 (-3.3; 0.2)	-2.2 (-4.1; -0.3)	9,106/9,632 (95%)	-1.7 (-4.0; 0.6)	-1.6 (-4.1; 1.0)
Location	Rural	16,004/18,965 (84%)	reference	reference	12,313/13,035 (94%)	reference	reference
	Urban	24,374/30,562 (80%)	-4.6 (-6.3; -3.0)	-3.7 (-5.9; -1.6)	19,803/20,507 (97%)	2.1 (0.0; 4.2)	1.0 (-1.8; 3.8)
Province	GP	10,396/13,281 (78%)	reference	reference	8,349/8,578 (97%)	reference	reference
	KZN	14,867/18,068 (82%)	4.0 (2.0; 6.0)	3.1 (0.8; 5.4)	12,485/12,969 (96%)	-1.1 (-3.8; 1.6)	-0.4 (-3.5; 2.7)
	MP	15,115/18,178 (83%)	4.9 (2.9; 6.9)	2.7 (0.2; 5.2)	11,282/11,995 (94%)	-3.3 (-6.0; -0.6)	-2.0 (-5.4; 1.4)
Years on ART	1-<2	8,229/10,485 (78%)	-5.0 (-7.2; -2.9)	-4.4 (-6.9; -1.9)	6,524/6,854 (95%)	-1.2 (-4.0; 1.7)	-0.9 (-4.2; 2.4)
	2-<5	17,295/21,256 (81%)	-2.1 (-4.0; -0.3)	-1.8 (-3.8; 0.3)	13,644/14,286 (96%)	-0.8 (-3.2; 1.5)	-0.7 (-3.4; 1.9)
	5+	14,854/17,786 (84%)	reference	reference	11,948/12,402 (96%)	reference	reference
WHO stage at ART	1	21,334/26,314 (81%)	reference	reference	17,241/17,846 (97%)	reference	reference
initiation	2	7,632/9,252 (82%)	1.4 (-0.7; 3.6)	0.2 (-2.0; 2.4)	5,860/6,200 (95%)	-2.1 (-4.9; 0.7)	-1.7 (-4.6; 1.2)
	3	4,806/5,951 (81%)	-0.3 (-2.8; 2.2)	-1.4 (-3.9; 1.2)	3,787/4,004 (95%)	-2.0 (-5.3; 1.3)	-2.1 (-5.4; 1.4)
	4	769/928 (83%)	1.8 (-4.0; 7.9)	0.7 (-5.2; 6.8)	631/666 (95%)	-1.9 (-9.2; 5.9)	-2.1 (-9.4; 5.7)

Table S4. Pooled adjusted risk difference (%) of retention in care and viral suppression by DSD enrolment at 12, 24 and 36 months, adjusting for CD4 count at ART initiation

		Retention in care		Viral suppression			
		Retained/N (%)	Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)	Virally suppressed/N* (%)	Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)
12 months							
DSD enrolment	No	93,966/103,786 (91%)	reference	reference	74,108/77,643 (95%)	reference	reference
	Yes	18,583/19,881 (93%)	2.9 (1.5; 4.4)	3.0 (1.3; 4.7)	14,824/15,320 (97%)	1.3 (-0.4; 3.0)	1.4 (-0.5; 3.3)
Age group (years)	18-24	5,010/5,883 (85%)	-7.3 (-9.7; -4.7)	-6.2 (-9.2; -3.1)	3,788/4,096 (92%)	-3.6 (-6.6; -0.4)	-3.7 (-7.4; 0.0)
	25-34	30,506/34,203 (89%)	-3.2 (-4.5; -1.9)	-2.8 (-4.3; -1.3)	23,878/25,100 (95%)	-0.9 (-2.4; 0.6)	-1.2 (-2.9; 0.6)
	35-49	53,175/57,542 (92%)	reference	reference	42,307/44,051 (96%)	reference	reference
	50+	23,858/26,039 (92%)	-0.8 (-2.2; 0.6)	-0.9 (-2.5; 0.7)	18,959/19,716 (96%)	0.1 (-1.5; 1.8)	0.2 (-1.6; 2.1)
Gender	Female	78,225/85,960 (91%)	reference	reference	62,330/64,863 (96%)	reference	reference
	Male	34,324/37,707 (91%)	0.0 (-1.1; 1.2)	-0.6 (-1.9; 0.7)	26,602/28,100 (95%)	-1.4 (-2.8; -0.1)	-1.6 (-3.2; 0.0)
Location	Rural	38,137/41,278 (92%)	reference	reference	29,723/31,548 (94%)	reference	reference
	Urban	74,412/82,389 (90%)	-2.1 (-3.2; -0.9)	-1.9 (-3.6; -0.3)	59,209/61,415 (96%)	2.2 (0.9; 3.5)	1.0 (-1.0; 2.9)
Province	GP	42,750/47,423 (90%)	reference	reference	33,615/34,716 (97%)	reference	reference
	KZN	33,793/37,065 (91%)	1.0 (-0.3; 2.3)	1.1 (-0.5; 2.7)	28,242/29,365 (96%)	-0.7 (-2.2; 0.9)	0.2 (-1.7; 2.1)
	MP	36,006/39,179 (92%)	1.8 (0.5; 3.0)	0.7 (-1.1; 2.6)	27,075/28,882 (94%)	-3.1 (-4.6; -1.6)	-2.6 (-4.8; -0.3)
Years on ART	1-<2	20,108/22,711 (89%)	-3.8 (-5.3; -2.3)	-2.7 (-4.5; -0.8)	16,016/16,806 (95%)	-0.6 (-2.4; 1.2)	-0.5 (-2.7; 1.7)
	2-<5	47,995/52,818 (91%)	-1.5 (-2.6; -0.3)	-0.7 (-2.1; 0.6)	37,571/39,298 (96%)	-0.3 (-1.7; 1.1)	-0.2 (-1.8; 1.5)
	5+	44,446/48,138 (92%)	reference	reference	35,345/36,859 (96%)	reference	reference
CD4 (cells/µl) at ART	<200	36,949/40,107 (92%)	reference	reference	29,048/30,594 (95%)	reference	reference
initiation	200-349	27,694/30,341 (91%)	-0.9 (-2.3; 0.6)	-0.5 (-2.0; 0.9)	21,964/22,857 (96%)	1.1 (-0.5; 2.8)	1.3 (-0.4; 3.0)
	350-499	13,619/15,004 (91%)	-1.4 (-3.1; 0.4)	-0.5 (-2.3; 1.4)	10,726/11,165 (96%)	1.1 (-1.0; 3.2)	1.5 (-0.7; 3.7)
	500+	11,282/12,636 (89%)	-2.8 (-4.7; -0.9)	-1.6 (-3.6; 0.4)	9,071/9,361 (97%)	2.0 (-0.3; 4.2)	2.3 (0.0; 4.7)
24 months							
DSD enrolment	No	61,943/72,788 (85%)	reference	reference	48,637/51,107 (95%)	reference	reference
	Yes	12,203/13,733 (89%)	3.8 (2.1; 5.5)	3.8 (1.9; 5.8)	9,943/10,241 (97%)	1.9 (-0.2; 4)	1.8 (-0.5; 4.1)
Age group (years)	18-24	3,102/4,031 (77%)	-10.7 (-13.6; -7.9)	-9.7 (-13.1; -6.1)	2,342/2,551 (92%)	-4.2 (-8.0; -0.3)	-3.8 (-8.5; 0.9)
	25-34	20,214/24,142 (84%)	-4.0 (-5.4; -2.5)	-3.5 (-5.2; -1.8)	15,752/16,652 (95%)	-1.4 (-3.3; 0.4)	-1.8 (-3.9; 0.3)
	35-49	35,234/40,178 (88%)	reference	reference	28,080/29,248 (96%)	reference	reference
	50+	15,596/18,170 (86%)	-1.9 (-3.5; -0.2)	-2.0 (-3.8; -0.1)	12,406/12,897 (96%)	0.2 (-1.8; 2.2)	0.4 (-1.9; 2.7)
Gender	Female	51,960/60,536 (86%)	reference	reference	41,421/43,186 (96%)	reference	reference
	Male	22,186/25,985 (85%)	-0.5 (-1.8; 0.9)	-1.3 (-2.8; 0.3)	17,159/18,162 (94%)	-1.4 (-3.1; 0.3)	-1.6 (-3.5; 0.3)
Location	Rural	26,638/30,270 (88%)	reference	reference	20,544/21,884 (94%)	reference	reference
	Urban	47,508/56,251 (84%)	-3.5 (-4.8; -2.2)	-3.1 (-5.0; -1.3)	38,036/39,464 (96%)	2.5 (0.9; 4.1)	0.6 (-1.7; 2.9)
Province	GP	24,846/29,616 (84%)	reference	reference	19,713/20,294 (97%)	reference	reference
	KZN	23,537/27,290 (86%)	2.4 (0.8; 3.9)	2.3 (0.4; 4.1)	19,762/20,596 (96%)	-1.2 (-3.1; 0.7)	-0.6 (-2.9; 1.7)
	MP	25,763/29,615 (87%)	3.1 (1.6; 4.6)	1.7 (-0.4; 3.8)	19,105/20,458 (93%)	-3.8 (-5.6; -1.9)	-3.6 (-6.2; -0.9)
Years on ART	1-<2	13,513/16,314 (83%)	-4.5 (-6.3; -2.8)	-3.2 (-5.3; -1.0)	10,648/11,197 (95%)	-0.9 (-3.1; 1.3)	-0.9 (-3.6; 1.8)
	2-<5	32,288/37,761 (86%)	-1.9 (-3.2; -0.5)	-1.1 (-2.8; 0.5)	25,282/26,561 (95%)	-0.8 (-2.5; 0.9)	-1.0 (-3.0; 1.0)
	5+	28,345/32,446 (87%)	reference	reference	22,650/23,590 (96%)	reference	reference
	<200	24,666/28,327 (87%)	reference	reference	19,386/20,496 (95%)	reference	reference

			Retention in care			Viral suppression	
		Retained/N (%)	Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)	Virally suppressed/N* (%)	Unadjusted risk difference (95% confidence interval)	Adjusted risk difference (95% confidence interval)
	200-349	18,965/22,058 (86%)	-1.1 (-2.7; 0.5)	-0.7 (-2.4; 0.9)	15,103/15,735 (96%)	1.4 (-0.6; 3.4)	1.8 (-0.3; 3.8)
CD4 (cells/µl) at ART	350-499	9,030/10,559 (86%)	-1.6 (-3.6; 0.5)	-0.5 (-2.6; 1.7)	7,093/7,382 (96%)	1.5 (-1.1; 4.1)	2.3 (-0.4; 5.0)
Initiation	500+	6,879/8,241 (83%)	-3.6 (-5.8; -1.3)	-2.1 (-4.4; 0.3)	5,512/5,701 (97%)	2.1 (-0.8; 5.0)	2.9 (-0.1; 5.9)
36 months							
DSD enrolment	No	33,568/41,512 (81%)	reference	reference	26,481/27,735 (95%)	reference	reference
	Yes	6,810/8,015 (85%)	4.1 (1.9; 6.3)	3.7 (1.3; 6.2)	5,635/5,807 (97%)	1.6 (-1.2; 4.4)	1.5 (-1.5; 4.6)
Age group (years)	18-24	1,679/2,351 (71%)	-12.4 (-16.0; -8.7)	-11.6 (-15.8; -7.2)	1,273/1,372 (93%)	-3.3 (-8.6; 2.1)	-2.8 (-9.0; 3.7)
	25-34	11,162/13,950 (80%)	-3.8 (-5.7; -1.9)	-3.4 (-5.6; -1.3)	8,792/9,259 (95%)	-1.2 (-3.6; 1.4)	-1.4 (-4.3; 1.4)
	35-49	19,090/22,773 (84%)	reference	reference	15,356/15,978 (96%)	reference	reference
	50+	8,447/10,453 (81%)	-3.0 (-5.1; -0.9)	-3.0 (-5.3; -0.6)	6,695/6,933 (97%)	0.5 (-2.3; 3.2)	0.5 (-2.6; 3.6)
Gender	Female	28,593/34,875 (82%)	reference	reference	23,010/23,910 (96%)	reference	reference
	Male	11,785/14,652 (80%)	-1.6 (-3.3; 0.2)	-2.5 (-4.4; -0.5)	9,106/9,632 (95%)	-1.7 (-4.0; 0.6)	-1.9 (-4.5; 0.7)
Location	Rural	16,004/18,965 (84%)	reference	reference	12,313/13,035 (94%)	reference	reference
	Urban	24,374/30,562 (80%)	-4.6 (-6.3; -3.0)	-3.9 (-6.2; -1.7)	19,803/20,507 (97%)	2.1 (0; 4.2)	0.8 (-2.1; 3.7)
Province	GP	10,396/13,281 (78%)	reference	reference	8,349/8,578 (97%)	reference	reference
	KZN	14,867/18,068 (82%)	4.0 (2.0; 6.0)	3.5 (1.1; 5.9)	12,485/12,969 (96%)	-1.1 (-3.8; 1.6)	-0.5 (-3.7; 2.7)
	MP	15,115/18,178 (83%)	4.9 (2.9; 6.9)	2.6 (-0.1; 5.3)	11,282/11,995 (94%)	-3.3 (-6.0; -0.6)	-2.7 (-6.3; 1.0)
Years on ART	1-<2	8,229/10,485 (78%)	-5.0 (-7.2; -2.9)	-3.7 (-6.3; -1.0)	6,524/6,854 (95%)	-1.2 (-4.0; 1.7)	-1.2 (-4.7; 2.3)
	2-<5	17,295/21,256 (81%)	-2.1 (-4.0; -0.3)	-1.6 (-3.7; 0.5)	13,644/14,286 (96%)	-0.8 (-3.2; 1.5)	-1.0 (-3.7; 1.7)
	5+	14,854/17,786 (84%)	reference	reference	11,948/12,402 (96%)	reference	reference
CD4 (cells/µl) at ART	<200	13,478/16,254 (83%)	reference	reference	10,662/11,214 (95%)	reference	reference
initiation	200-349	10,881/13,225 (82%)	-0.6 (-2.7; 1.4)	-0.3 (-2.4; 1.8)	8,762/9,099 (96%)	1.2 (-1.5; 3.9)	1.5 (-1.3; 4.2)
	350-499	4,991/6,161 (81%)	-1.9 (-4.5; 0.7)	-0.8 (-3.5; 2.0)	3,996/4,161 (96%)	1.0 (-2.5; 4.5)	1.5 (-2.1; 5.2)
	500+	3,472/4,422 (79%)	-4.4 (-7.3; -1.4)	-2.7 (-5.8; 0.4)	2,814/2,919 (96%)	1.3 (-2.6; 5.4)	1.8 (-2.4; 6.0)

*denominator only includes those with a viral load measured during the 12-, 24- or 36-month outcome periods

40 Table S5. Age-stratified pooled risk differences for retention

Age group	n/N (%) retained in DSD	n/N (%) retained in non-DSD	Unadjusted Risk Difference comparing DSD vs non-DSD (95% CI)	Adjusted Risk Difference comparing DSD vs non-DSD (95% CI)
		12 m	nonths	
18-24	660/745 (89%)	4,350/5,138 (85%)	3.9 (-3.1; 11.3)	4.4 (-3.2; 12.3)
25-34	5,268/5,713 (92%)	25,238/28,491 (89%)	3.6 (0.9; 6.4)	4.1 (1.3; 7.0)
35-49	9,241/9,797 (94%)	43,934/47,745 (92%)	2.3 (0.2; 4.4)	2.5 (0.3; 4.8)
50+	3,414/3,627 (94%)	20,444/22,412 (91%)	2.9 (-0.5; 6.3)	3.0 (-0.6; 6.7)
		24 m	nonths	
18-24	422/505 (84%)	2,680/3,526 (76%)	7.6 (-0.7; 16.3)	7.8 (-1.2; 17.2)
25-34	3,469/3,990 (87%)	16,745/20,153 (83%)	3.9 (0.7; 7.0)	4.7 (1.4; 8.1)
35-49	6,087/6,743 (90%)	29,147/33,435 (87%)	3.1 (0.6; 5.6)	3.5 (0.9; 6.2)
50+	2,225/2,496 (89%)	13,371/15,674 (85%)	3.8 (-0.1; 7.9)	4.1 (-0.1; 8.5)
		36 m	onths	
18-24	234/301 (78%)	1,445/2,050 (70%)	7.3 (-3.0; 18.2)	7.0 (-4.2; 19.0)
25-34	1,982/2,400 (83%)	9,180/11,550 (79%)	3.1 (-0.8; 7.1)	3.6 (-0.6; 8.0)
35-49	3,381/3,892 (87%)	15,709/18,881 (83%)	3.7 (0.5; 6.9)	4.2 (0.7; 7.8)
50+	1,213/1,422 (85%)	7,234/9,031 (80%)	5.2 (0.1; 10.4)	5.4 (-0.1; 11.1)

43

45 Table S6. Age-stratified pooled risk differences for viral suppression

Age group	n/N (%) virally suppressed* in DSD	n/N (%) virally suppressed in non-DSD	Unadjusted Risk Difference comparing DSD vs non-DSD (95% Cl)	Adjusted Risk Difference comparing DSD vs non-DSD (95% Cl)
		12 mor	iths	
18-24	531/555 (96%)	3,257/3,541 (92%)	3.7 (-4.8; 12.6)	3.3 (-5.9; 12.9)
25-34	4,171/4,335 (96%)	19,706/20,765 (95%)	1.3 (-1.9; 4.5)	1.4 (-2.0; 4.8)
35-49	7,404/7,627 (97%)	34,901/36,424 (96%)	1.3 (-1.2; 3.7)	1.2 (-1.3; 3.8)
50+	2,717/2,803 (97%)	16,236/16,913 (96%)	0.9 (-3.0; 4.9)	1.3 (-2.9; 5.6)
		24 mor	iths	
18-24	329/347 (95%)	2,013/2,204 (91%)	3.5 (-7.2; 14.8)	4.1 (-7.6; 16.6)
25-34	2,780/2,891 (96%)	12,972/13,762 (94%)	1.9 (-2.0; 5.9)	1.3 (-2.8; 5.6)
35-49	5,002/5,129 (98%)	23,075/24,119 (96%)	1.9 (-1.1; 4.8)	1.7 (-1.5; 4.9)
50+	1,829/1,874 (98%)	10,575/11,023 (96%)	1.7 (-3.1; 6.6)	1.6 (-3.5; 6.9)
		36 mor	iths	
18-24	196/200 (98%)	1,077/1,172 (92%)	6.1 (-8.1; 21.4)	6.1 (-9.7; 23.3)
25-34	1,629/1,688 (97%)	7,161/7,571 (95%)	1.9 (-3.2; 7.2)	1.6 (-3.8; 7.3)
35-49	2,811/2,900 (97%)	12,543/13,078 (96%)	1.0 (-2.9; 5.0)	0.9 (-3.4; 5.2)
50+	999/1,019 (98%)	5,695/5,914 (96%)	1.7 (-4.7; 8.4)	1.6 (-5.4; 8.9)

47 *Viral suppression defined as having a viral load of <400 copies/ml

50 Table S7. Sex-stratified pooled risk differences for viral suppression

	n/N (%) retained	n/N (%) retained	Unadjusted Risk Difference comparing DSD vs non-DSD	Adjusted Risk Difference comparing DSD vs non-DSD
Age group	in DSD	in non-DSD	(95% CI)	(95% CI)
		12 m	onths	
Female	13,090/13,991 (94%)	65,135/71,970 (91%)	3.1 (1.3; 4.8)	3.2 (1.3; 5.0)
Male	5,493/5,891 (93%)	28,831/31,816 (91%)	2.6 (0.0; 5.3)	3.1 (0.3; 6.0)
		24 ma	onths	
Female	8,678/9,755 (89%)	43,282/50,782 (85%)	3.7 (1.7; 5.8)	4.1 (1.9; 6.3)
Male	3,525/3,979 (89%)	18,661/22,006 (85%)	3.8 (0.6; 7.0)	4.3 (1.0; 7.8)
		36 m	onths	
Female	4,924/5,756 (86%)	23,669/29,119 (81%)	4.3 (1.7; 6.9)	4.4 (1.5; 7.2)
Male	1,886/2,259 (83%)	9,899/12,393 (80%)	3.6 (-0.4; 7.7)	4.4 (0.0; 8.9)

Table S8. Sex-stratified pooled risk differences for viral suppression

Age	n/N (%) virally	n/N (%) virally	Unadjusted Risk Difference comparing DSD vs non-DSD	Adjusted Risk Difference comparing DSD vs non-DSD			
group	suppressed in DSD	suppressed in non-DSD	(95% CI)	(95% CI)			
		12 mor	nths				
Female	10,532/10,861 (97%)	51,790/54,002 (96%)	1.1 (-1.0; 3.1)	1.1 (-1.0; 3.3)			
Male	4,291/4,459 (96%)	22,310/23,641 (94%)	1.9 (-1.2; 5.0)	1.8 (-1.5; 5.2)			
		24 mor	nths				
Female	7,106/7,307 (97%)	34,313/35,880 (96%)	1.6 (-0.8; 4.1)	1.5 (-1.2; 4.1)			
Male	2,834/2,934 (97%)	14,322/15,228 (94%)	2.5 (-1.3; 6.5)	2.2 (-1.9; 6.3)			
36 months							
Female	4,119/4,237 (97%)	18,889/19,673 (96%)	1.2 (-2.0; 4.5)	1.2 (-2.3; 4.8)			
Male	1,516/1,570 (97%)	7,587/8,062 (94%)	2.5 (-2.8; 7.8)	1.9 (-3.8; 7.7)			